



Title	Cytoplasmic Fragment of Alcadein alpha Generated by Regulated Intramembrane Proteolysis Enhances Amyloid beta-Protein Precursor (APP) Transport into the Late Secretory Pathway and Facilitates APP Cleavage
Author(s)	Takei, Norio; Sobu, Yuriko; Kimura, Ayano et al.
Citation	Journal of biological chemistry, 290(2), 987-995 https://doi.org/10.1074/jbc.M114.599852
Issue Date	2015-01-09
Doc URL	https://hdl.handle.net/2115/58151
Rights	This research was originally published in Journal of Biological Chemistry. Takei N., et al. Cytoplasmic fragment of Alcadein α generated by regulated intramembrane proteolysis enhances amyloid β -protein precursor (APP) transport into the late secretory pathway and facilitates APP cleavage. Journal of Biological Chemistry. 2015; 290(2):987-995. © the American Society for Biochemistry and Molecular Biology.
Type	journal article
File Information	WoS_68402_Suzuki.pdf



Cytoplasmic Fragment of Alcadein α Generated by Regulated Intramembrane Proteolysis Enhances APP Transport into the Late-Secretory Pathway and Facilitates APP Cleavage[¶]

Running title: Alcadein RIP fragment regulates APP trafficking and metabolism

Norio Takei¹, Yuriko Sobu¹, Ayano Kimura¹, Satomi Urano¹, Yi Piao¹, Yoichi Araki¹, Hidenori Taru¹, Tohru Yamamoto², Saori Hata¹, Tadashi Nakaya¹ and Toshiharu Suzuki^{1§}

¹Laboratory of Neuroscience, Graduate School of Pharmaceutical Sciences, Hokkaido University, Kita-12 Nishi-6, Kita-ku, Sapporo 060-0812, Japan. ²Department of Molecular Neurobiology, Faculty of Medicine, Kagawa University, Miki-cho 761-0793, Japan.

[§]To whom correspondence should be addressed: E-mail: tsuzuki@pharm.hokudai.ac.jp
Tel: 81-11-706-3250; Fax: 81-11-706-4991

Keywords: Alzheimer disease, γ -secretase, regulated intramembrane proteolysis, Alcadein

Background: Alcadein α (Alc α) forms a ternary complex with APP and X11L.

Results: Transport into the nerve terminus and metabolism of APP were facilitated in Alc α CTF transgenic mice, along with an increase in A β .

Conclusion: Alc α ICD, a product of γ -secretase cleavage of Alc α CTF, enhanced APP trafficking from the ternary complex into a late-secretory pathway.

Significance: Novel function of Alcadein α results from regulated intramembrane proteolysis.

Abstract

The neural type I membrane protein Alcadein α (Alc α), is primarily cleaved by β -amyloid precursor protein (APP) α -secretase to generate a membrane-associated carboxyl-terminal fragment (Alc α CTF), which is further cleaved by γ -secretase to secrete p3-Alc α peptides and generate an intracellular cytoplasmic domain fragment (Alc α ICD) in the late-secretory pathway. By association with the neural adaptor protein X11-like (X11L), Alc α and APP form a ternary complex that suppresses the cleavage of both Alc α and APP by regulating the transport of these membrane proteins into the late-secretory pathway where secretases are active. However, it has not been revealed how Alc α and APP are directed from the ternary complex formed largely in the Golgi into the late-secretory pathway to reach a nerve terminus. Using a novel transgenic mouse line expressing excess amounts of human Alc α CTF (hAlc α CTF) in neurons, we found that

expression of hAlc α CTF induced excess production of hAlc α ICD, which facilitated APP transport into the nerve terminus and enhanced APP metabolism, including A β generation. *In vitro* cell studies also demonstrated that excess expression of Alc α ICD released both APP and Alc α from the ternary complex. These results indicate that regulated intramembrane proteolysis (RIP) of Alc α by γ -secretase regulates APP trafficking and the production of A β *in vivo*.

Introduction

Alcadin (Alc) is a brain abundant type I membrane protein family comprised of Alc α , Alc β and Alc γ (1), which are also identified as the Ca²⁺-binding proteins calsynenins (2, 3). They share two cadherin repeats, a Concanavalin A-like lectin/glucanase superfamily domain in their amino-terminal extracellular region, an acidic domain, a kinesin light chain-binding WD motif and an X11-like (X11L)-binding NP sequence in their carboxy-terminal cytoplasmic region (1, 4). Originally, we isolated Alc α as an X11L-interacting molecule (1, 5). X11L is a neuron-specific cytoplasmic adaptor protein and was also identified as a binding partner of amyloid- β protein precursor (APP) (6). Both Alc α and APP interact with the phosphotyrosine interaction (PI)/phosphotyrosine-binding (PTB) domain of X11L and form a ternary complex comprised of Alc α , X11L and APP (1, 5).

In neurons, APP695, a neuron-specific isoform, undergoes *N*-glycosylation in the endoplasmic reticulum (ER), producing immature APP (imAPP) (7). The imAPP is

transported to the Golgi and further modified by *O*-glycosylation to form mature APP (mAPP). The mAPP enters into the late-secretory pathway and localizes to the plasma membrane, while some mAPP also enters endosomal recycling pathways. During the late-secretory pathway, APP is subject to consecutive cleavages (8). Alca/calsynenin-1 is also subject to intracellular trafficking and metabolism, and participates in neural functions, similar to APP (4, 9-11). Calsynenins have also been reported to mediate exit of APP from the TGN (12).

It is well-known that APP undergoes primary proteolytic cleavage at juxtamembrane α - or β -sites by α - or β -secretase, and that membrane-associated APP C-terminal fragments (APP CTFs) are further cleaved at γ/ϵ -sites by γ -secretase (8). When APP is cleaved by a combination of α - and γ -secretases, a metabolically labile p3 peptide is generated, while neurotoxic amyloid β (A β) peptide is generated when APP is cleaved by β - and γ -secretases. The A β peptide is known as a causative molecule of Alzheimer disease (AD) (13, 14). Alca is also subject to proteolytic cleavage by α -secretase and remains a membrane-associated C-terminal fragment (Alca CTF), which is further cleaved by γ -secretase to secrete p3-Alca and generate an intracellular domain fragment (Alca ICD) (10, 15).

X11L associates with both APP and Alca in the Golgi and also in the late-secretory pathway (16, 17). In the Golgi, X11L is thought to regulate the formation of APP and Alca cargo vesicles (17). Formation of the ternary complex composed of APP, X11L and Alca also regulates the entry of APP into lipid rafts where β -secretase is active (16). Additionally, X11L is thought to regulate γ -cleavage of APP CTFs directly (18).

A β production is suppressed when APP is expressed with X11L, and we reported that suppressed A β production by X11L was further enhanced when full-length Alca was also coexpressed (1, 5, 6) due to ternary complex formation. *In vitro*, binding of APP to X11L is stabilized when Alca is coexpressed, and this enhanced interaction of APP with X11L mediated by Alca is thought to further stabilize APP metabolism as well as regulate intracellular APP trafficking because the cleavage of APP by secretases occurs in the late-secretory pathway.

In vivo, X11L/X11 β transgenic mice expressing human APP suppressed amyloidogenic processing of APP (19). Furthermore, X11L gene knockout (X11L-KO) mice showed enhanced generation of endogenous A β in the brain (20), and human APP transgenic mice lacking the X11L gene exhibited enhanced amyloid plaque formation in the brain (21). However, the role of Alca metabolites in APP metabolism and A β generation remain unclear *in vivo*. To determine the function of Alca CTF and its intracellular metabolic fragment Alca ICD, we generated a transgenic mouse line expressing human Alca-CTF under the control of the PDGF- β promoter and examined its effect on the metabolism of APP *in vivo*.

Experimental Procedures

Generation of hAlca CTF transgenic mouse lines

cDNA encoding human Alca CTF (amino acids 817 to 971 of the hAlca1 isoform) (1, 10) was connected to the signal sequence (amino acids 1 to 28 of hAlca1). The construct was inserted into a vector with a 5' PDGF- β promoter and a 3' SV40 polyA tail to produce the TgPDhAlcaCTF plasmid. For DNA microinjection, linearized DNA was prepared by digestion with restriction enzymes, as illustrated (Fig. 1A). Mice were purchased from CLEA-Japan (Tokyo, Japan), and all of the animal studies were conducted in compliance with the guidelines of the Animal Studies Committee of Hokkaido University. Linearized DNA (*Sall/NotI* fragment) was micro-injected into fertilized eggs produced by mating between BDF1 mice (F1 hybrid of C57BL/6 and DBA/2 mice) according to standard procedures (22). In brief, BDF1 females (6–8 weeks of age) that had been super-ovulated by injection of pregnant mare serum gonadotropin (serotropin, Asuka Pharmaceutical Co.) and human chorionic gonadotropin (Asuka Pharmaceutical Co.) were mated with males of the same strain. Pronuclear stage embryos were collected from pregnant females and DNA fragments were injected into the male pronuclei of the zygotes. The embryos were then cultured in potassium simplex optimized medium at 37°C in an atmosphere of 5% CO₂ and 95% humidity. The surviving embryos were transplanted into the oviducts of pseudo-pregnant females (MCH (ICR), 8–12 weeks of age). Transgenic founders were identified by PCR and Southern blot analysis of

genomic DNA extracted from tail biopsies. Genotyping PCR was performed using a set of sense (Alc α CTF, 5'-cct gac cat cac cgt caa cc-3') and antisense (SV40, 5'-cac ctc ccc ctg aac ctg aa-3') primers with ExTaq DNA polymerase (Takara-bio, Japan). For Southern blot analysis, genomic DNA was digested with *EcoRI*, separated by agarose-gel electrophoresis, and transferred onto a Nylon membrane. The membrane was incubated with a probe prepared from the DNA sequence of an injected construct and signals were detected by CDP-Star (GE Healthcare). Founder mice were backcrossed with C57BL/6 mice, and offspring were backcrossed over 10 times. Non-transgenic littermates derived from the same crosses were used as controls.

MALDI-TOF/MS analysis of p3-Alc α in the medium of cells expressing human Alc α CTF

Tg construct was recloned into pcDNA3.1 to generate pcDNA3.1-hAlc α CTF. The p3-Alc α peptides secreted into the medium of HEK293 cells transiently transfected with pcDNA3.1-hAlc α CTF was recovered by immunoprecipitation with anti-p3-Alc α UT135 antibody and Protein G-Sepharose beads (10). The beads were washed and sample was eluted with trifluoroacetic acid/acetonitrile/water (1:20:20) saturated with sinapinic acid. The dissolved sample was subject to MALDI-TOF/MS analysis with a UltraflexII TOF/TOF (Bruker Daltonics, Bremen Germany) (10).

Immunohistochemistry

Mouse brain sections (25 μ m thick) were prepared as described (20), and the sections were stored at -30°C until use. Frozen sections were washed with PBS for 20 min and then incubated in PBS containing 1% (v/v) Triton X-100 for 20 min to permeabilize the membranes. Tissue sections were then incubated with PBS containing 0.3% (v/v) H₂O₂ for 10 min to inactivate endogenous peroxidase activity and washed three times with PBS. The sections were blocked with PBS containing 5% (v/v) normal goat serum for 1 hr at rt and then incubated with #958 antibody (serum diluted to 1:8,000) for approximately 8hr at 4°C. After three washes with PBS, sections were incubated with an anti-rabbit IgG peroxidase-linked species-specific whole antibody (GE Healthcare, dilution 1:500) for 30 min at rt. The signal was visualized with

VECTASTAIN kit (Vector Laboratories) following the manufacturer's protocol.

Subcellular fractionation

The cytosolic fraction of mouse brain tissue was prepared as described (23), and subjected to immunoprecipitation with #958 antibody. The synaptosome fraction was prepared as described (24) with some modifications. In brief, the cerebral cortex and hippocampus regions of 12-month-old Tg54 and non-Tg mice were homogenized in buffer A [10 mM HEPES (pH 7.4) containing 0.32 M sucrose, 5 μ g/ml chymostatin and 5 μ g/ml leupeptin], and this fraction was used as total lysate (Lys). The lysate was then centrifuged at 1,000 x g for 10 min and a clarified supernatant (S1 fraction) was recovered. The S1 fraction was further centrifuged at 13,800 x g for 20 min and the supernatant (S2 fraction) and pellet (P2 fraction) were used for assays. The P2 fraction was suspended again in buffer A and overlaid on a discontinuous sucrose gradient prepared with 1.2 M, 1 M and 0.85 M sucrose solution and centrifuged at 82,500 x g for 2 hr with an SW41 rotor (Beckman Coulter). After centrifugation, the layer between 1.0 M and 1.2 M sucrose was collected and resuspended in 6 mM Tris-HCl [pH 8.0] buffer containing 0.5% (v/v) Triton X-100 to prepare the synaptosome (Syn) fraction.

Antibodies, immunoprecipitation and immunoblot analysis

A rabbit polyclonal anti-Alc α carboxyl-terminal domain antibody, #958, was raised against a synthesized peptide, 948-GEQGD PQNATRQQQL-962, of human Alc α 1. IgG was affinity purified with antigen-coupled beads and used for analyses. This antibody specifically recognizes Alc α of human and mouse almost equivalently, but does not show cross-reactivity with Alc β and Alc γ of human (Fig. 2A) or mouse (data not shown).

Immunoprecipitation was performed as described (1) using a previously-described plasmid for FLAG-X11L (6). For the APP-GFP construct, human APP695 was cloned into pEGFP-N3 (Clontech) between the *HindIII/NotI* sites. For the hAlc α ICD construct, cDNA encoding the cytoplasmic region of hAlc α from 868 to 971 a.a. was cloned into pcDNA3.1. Amino acid position 868 of Alc α 1 is the major N-terminus of Alc α ICD, which is generated by ϵ -cleavage of Alc α CTF by γ -secretase (15).

Brain and cell extracts used in immunoblot analyses were prepared by homogenizing samples in eight volumes of RIPA buffer containing 5 µg/ml chymostatin and 5 µg/ml leupeptin. The lysates were centrifuged and supernatants were used for immunoprecipitation analysis. The procedures used for immunoblotting and the identification of APP CTFs were described previously (25).

Antibodies used in immunoblot analysis were as follows: rabbit polyclonal anti-Alcα (#958) and anti-APP (#8717, Sigma), mouse monoclonal anti-FLAG (M2, Sigma), anti-flotillin-1 (BD Bioscience), anti-synaptophysin (SY38, DAKO), anti-α-tubulin (sc-32293, SantaCruz), anti-GM130 (BD Bioscience), anti-GFP (#598, MBL) and anti-β-actin (ab8226, Abcam). For quantification of immunoreactive proteins, a VersaDoc system (Bio-Rad) or LAS-4000 mini (Fujifilm) was used. The intensities of the protein bands of Alcα CTF, APP full-length and APP CTFs were normalized to the values of flotillin-1.

sELISA for quantification of mouse Aβ and p3-Alcα

To quantify Aβ in mice brains, the cerebral cortex and hippocampus were excised from 12- to 15-month-old mice, and TBS-soluble and -insoluble fractions were prepared as described (16). Mouse Aβ¹⁻⁴⁰ and Aβ¹⁻⁴² in the TBS-soluble and -insoluble fractions were examined with a sELISA kit (Aβ¹⁻⁴⁰, #27720; Aβ¹⁻⁴², #27721; IBL, Takasaki, Japan). Quantification of p3-Alcα was described previously (26).

Immunofluorescence microscopy analysis and quantification of fluorescence intensity

The procedures in immunofluorescence experiments shown in Fig. 5 were followed as previously described (27). The images were analyzed by a fluorescence microscope (Keyence, BZ-700X). Fluorescence quantification was performed using the imaging software ImageJ (<http://imagej.nih.gov/ij/>, NIH). The images were acquired with a resolution of 640 x 480 pixels using a 100x objective lens, which covered the whole cell region. The region of interest that contained the cell body-neurite junction area was selected at a resolution of 132 pixels x 48 pixels, in which the junction was set to a middle region manually using a transparent image obtained by transmission light. The

fluorescence intensities in the proximal region of neurite (“neurite”, right half of a selected image) and the hillock of cell body (“cell body”, left half of a selected image) were then. The fluorescence intensities where no cell region was observed in the right and left half images were also measured as background. The background intensity was subtracted from the respective intensity of “cell body” and “neurite”, and the values were indicated as a ratio to average intensity of “neurite” plus “cell body”.

Results

Generation of human Alcα carboxyl-terminal fragment transgenic mice

A cDNA sequence encoding the carboxy-terminal region of human Alcα1 together with the signal peptide sequence was expressed under the regulation of the mouse PDGF-β promoter (Fig. 1A). The signal sequence was cleaved correctly by signal peptidase when expressed in HEK293 cells, producing the human Alcα carboxyl-terminal fragment (hAlcα CTF) with the correct amino-terminal sequence. hAlcα CTF then underwent intramembrane cleavage by γ-secretase to generate p3-Alcα with the same amino acid sequence observed *in vivo* (10). MALDI-TOF/MS analysis of p3-Alcα secreted from HEK293 cells showed that the p3-Alcα35 (the amino acid sequence is indicated in panel B) was generated as a major p3-Alcα form along with several minor species (Fig. 1B). The result indicates that exogenously expressed hAlcα CTF was processed in a manner similar to that of endogenously generated Alcα CTF.

We generated six transgenic mouse founder lines using this construct (Fig. 1C). Genomic Southern blot analysis of the six lines shows a few to several hundred copies of exogenous gene incorporated into the genome (Fig. 1D). The protein expression level of hAlcα CTF in the brain region including the cerebral cortex and hippocampus was analyzed in the three lines with the highest trans-gene dose by immunoblotting with an anti-Alcα antibody (Fig. 1E). Of these founders, line #54, which showed a 4-fold increase in hAlcα CTF expression compared to endogenous levels of the protein, was chosen for use in further analyses. Tg54 was subjected to genetic back-cross with C57BL/6 over ten generations.

Expression of hAlcα CTF in Tg54 mouse brain

Alcadein family proteins, Alcα, Alcβ and Alcγ, share a similar structure in the cytoplasmic region. Therefore, we developed an antibody raised against the cytoplasmic sequence of Alcα. This antibody, designated #958, recognizes specifically Alcα and its CTF, but not Alcβ or Alcγ. An anti-FLAG antibody was used to confirm the levels of expression in cells expressing these FLAG-tagged constructs (**Fig. 2A**).

Using this antibody, we analyzed the expression of hAlcα CTF in 3-month-old Tg54 (Tg) and non-Tg (N) mice (**Fig. 2B and C**). Under the regulation of the PDGF-β promoter, increased expression of hAlcα CTF was observed in the cerebral cortex, hippocampus and olfactory bulb in Tg compared to non-Tg mice (**Fig. 2B**). Immunohistochemical analysis of endogenous Alcα and hAlcα CTF expression agreed well with the results of immunoblot analysis. An immuno-reactive signal was observed throughout the cerebral cortex (**Fig. 2C panels a and d**), in pyramidal cells in CA1 to CA3 along with granule cells in the dentate gyrus of the hippocampus (**Fig. 2C panels b and e**), and in layers of mitral and granule cells of the olfactory bulb (**Fig. 2C panels c and f**). These signals were enhanced in Tg54 mouse brains (**Fig. 2C panels d–f**). Immunoreactivity of tissue staining is of specific because this antibody does not react to the tissue staining of Alcα-KO mouse brain (data not shown). Taken together, we concluded that the Tg line expressing hAlcα CTF, Tg54, was successfully established. Tg54 mice exhibit normal growth and fertility (data not shown).

We next measured the amounts of p3-Alcα, which is generated by γ-secretase cleavage of Alcα CTF (illustrated in **Fig. 2F**). In brains of Tg54 mice, the total amount of p3-Alcα greatly increased while in non-Tg mice it was below the level of detection (Tg: 0.33 ± 0.03 pmol/g tissue, $n = 3$, **Fig. 2D**). Corresponding to the increased amount of p3-Alcα in brain tissue, a significant amount of hAlcα ICD, which was detected as a doublet, was also detected in the cytosolic fraction of Tg54 mouse brain tissue, while only very low levels were detected in non-Tg mice (**Fig. 2E**). These findings indicate that exogenously expressed hAlcα CTF is physiologically cleaved by γ-secretase in the

brain to generate p3-Alcα along with Alcα ICD (**10, 15**).

Facilitation of intracellular trafficking and metabolism of endogenous mouse APP in Tg54 mice

To reveal the effect of Alcα CTF on the metabolism of APP *in vivo*, the amounts of endogenous Aβ¹⁻⁴⁰ and Aβ¹⁻⁴² in brain lysate isolated from the cerebral cortex and hippocampus were quantified in 12- to 15-month-old Tg54 and non-Tg mice. Unexpectedly, the amounts of both Aβ species were significantly greater in Tg54 than non-Tg mice [TBS insoluble Aβ¹⁻⁴⁰: non-Tg = 0.61 ± 0.04 pmol/g tissue, Tg54 = 0.72 ± 0.02 pmol/g tissue ($p=0.0017$); TBS insoluble Aβ¹⁻⁴²: non-Tg = 0.18 ± 0.00 pmol/g tissue, Tg54 = 0.22 ± 0.01 pmol/g tissue ($p=0.0105$)] (**Fig. 3A**). The amount of Aβ yielded in the TBS-soluble fraction was too small to detect a significant change. These results suggest that the metabolism of APP is facilitated in the brains of Tg54 mice.

Cleavage of APP in neurons occurs during or after its axonal transport; in other words, in the late-secretory pathway. Therefore, the brains of Tg54 and non-Tg mice were fractionated to isolate the synaptosome fraction, which includes membrane vesicles of the late-secretory pathway. As shown in Figure 3B, the amounts of full-length APP, especially mature APP (mAPP) in synaptosomes, was significantly greater in Tg54 mice [Syn = 1.24 ± 0.19 ($n=5$, $p=0.0458$) when the value in non-Tg mice was set at 1.0]. However, total APP, which includes mAPP and imAPP, was not changed significantly in the total lysate of either Tg or non-Tg mice (Lys = 1.06 ± 0.19 , $n=5$, $p=0.4904$). APP CTFs were also significantly more abundant in the synaptosome fraction of Tg54 mice compared to non-Tg mice [1.27 ± 0.09 ($n=7$, $p=0.0261$) when the value in non-Tg mice was set at 1.0], while the amounts were equivalent in total lysate of Tg54 and non-Tg mice (0.92 ± 0.05 , $n=7$, $p=0.1843$). These results suggest that increased amounts of APP undergo enhanced trafficking into the nerve terminus where it is cleaved by primary secretases. Increased CTFs in the late-secretory pathway are then further cleaved by γ-secretase in Tg54 mice, thus facilitating the production of Aβ in the brain. This is not the result of enhanced amyloidogenic processing of APP. Aβ^{1-40/1-42} is derived from C99 among three

CTF species; C99 (CTF β), C89 (CTF β) and C83 (CTF α). These CTFs are phosphorylated at Thr668 in brain, and the phosphorylated C99 (pC99) is a major C99 rather than non-phosphorylated form in mouse brain (7). Therefore, an increase of pC99 level can indicate the enhanced amyloidogenic cleavage of APP. However, in Figure 3B, the ratio of pC99 to total CTF was equivalent in the synaptosome fraction of Tg54 and non-Tg mice brains, although total amounts of APP CTFs increased significantly in the synaptosome fraction of Tg54. Therefore, we understand that the increased A β production in Tg54 is due to the facilitated trafficking of APP into the late-secretory pathway rather than the enhanced amyloidogenic cleavage of APP. Identification of mature and immature APP and APP CTF species in the brain was described in detail previously (7).

We then considered the possibility that hAlc α ICD derived from hAlc α CTF could play a role in processing the increased amounts of APP entering the late-secretory pathway, since the hAlc α ICD was free from membrane association and highly abundant in Tg54 (**Fig. 2F**). APP and Alc α are associated in the Golgi apparatus via interaction with X11 family proteins. Interaction of APP with X11L, a neuron-specific protein, is enhanced by association of Alc α with X11L. APP in this ternary complex is thought to suppress further trafficking into the late-secretory pathway, thus stabilizing APP for cleavage by secretases. In Tg54 mice, excess expression of hAlc α CTF is likely to relieve this suppression. hAlc α CTF is then quickly cleaved by γ -secretase to generate hAlc α ICD along with p3-Alc α (**Fig. 2D–E**). Thus, hAlc α ICD could perform a function different from full-length Alc α in stabilizing APP metabolism in the presence of X11L.

To assess this possibility, hAlc α ICD was coexpressed in Neuro2a cells, together with GFP-tagged hAPP (hAPP-GFP), full-length hAlc α (hAlc α FL) and FLAG-tagged X11L (FLAG-X11L), which form a ternary complex (**Fig. 4**). In the absence of hAlc α ICD, co-immunoprecipitation with an anti-FLAG antibody recovered FLAG-X11L together with hAPP-GFP and hAlc α FL (**Fig. 4A**, lane 5). However, increased expression of hAlc α ICD decreased the recovery of both hAPP-GFP and hAlc α FL significantly (**Fig. 4A**, lanes 6–8 and

4B), although hAPP-GFP, hAlc α FL and FLAG-X11L are expressed at equal levels (**Fig. 4A**, lanes 1–4). These results indicate that Alc α ICD performs a novel function that releases both APP and Alc α from X11L and is different from the function of Alc α FL. Thus, it is possible to conclude that the increased levels of APP and its metabolic fragments APP CTFs and A β in the synaptosome fraction of the brains of Tg54 mice is due to enhanced release and anterograde trafficking of APP to the nerve terminus from the cell body. In summary, Alc α ICD regulates the trafficking of APP and Alc α itself. This may be a novel function involved in RIP by γ -secretase (28, 29).

Alc α ICD regulates the trafficking of APP into neurites

To analyze the function of Alc α ICD on the trafficking of APP into neurites, we used Neuro2a cell which exhibits the extensions of neurites under a normal culture condition. In neuronal cells expressing EGFP-APP, APP appears the proximal region of extending neurites because APP is subject to an anterograde transport into the late-secretory pathway (4). Therefore, we analyzed quantitatively the fluorescence signals of EGFP-APP in the proximal region of neurites (**Fig. 5**).

When Alc α CTF was expressed in Neuro2a cells expressing EGFP-APP and HA-X11L, fluorescence signal of APP appears in the proximal neurite, while the signal reduced significantly in the presence of 10 mM DAPT (γ -secretase inhibitor: (3,5-Difluorophenylacetyl)-Ala-Phg-OBu^t) (**Fig. 5B and C**; upper panels). Cells treated with DAPT showed the increased Alc α CTF levels (**Fig. 5D**), suggesting the production of Alc α ICD by γ -secretase cleavage of Alc α CTF was inhibited.

When Alc α ICD was further expressed in the cells along with Alc α CTF expression, EGFP-APP fluorescence in the proximal region was not decreased by DAPT treatment (**Fig. 5B and C**; lower panels). These observations indicate that Alc α ICD, but not Alc α CTF, facilitates the trafficking of APP into the late-secretory pathway.

Discussion

Since it was documented that the generation of A β from APP and the formation of neurotoxic A β oligomers in neurons are closely linked to the etiology of AD, many efforts have been made to identify the modulator of APP metabolism, including A β generation and clearance (14). With regard to APP trafficking and metabolism, we and others have reported previously that X11 family proteins (X11s) are regulators of APP metabolism (6, 16, 20, 30-33). Excess expression of X11s suppresses APP processing, including A β generation and APP trafficking, via binding of X11L to APP. Furthermore, X11s function in the regulation of γ -cleavage of APP CTF directly or indirectly (18) or of β -cleavage of APP indirectly (16). Importantly, X11s-KO mice showed a significant increase in endogenous A β generation in the brain and increased formation of amyloid plaques was observed in the brains of hAPP-Tg/X11s-defective mice, indicating that X11s play an important role in APP regulation at various stages of APP metabolism and trafficking *in vivo* (16, 20, 21, 34, 35).

This effect is further enhanced in the presence of Al α by the formation of a metabolically stable ternary APP/X11L/Al α complex. This suggests that along with X11L, Al α may be a key molecule for APP metabolism and trafficking *in vivo*. Since our previous *in vitro* study indicated that not only Al α , but also Al α CTF, could form a ternary complex together with X11L and APP in cultured cells (1), we hypothesized that membrane-associated full-length Al α and Al α CTF would suppress the production of A β in the presence of X11L.

However, we observed that the brains of Tg54 mice expressing excess amounts of hAl α CTF showed a significant increase in A β due to enhanced transport of APP into the late-secretory pathway. Moreover, our analysis showed remarkable production of p3-Al α and Al α ICD, which are the products of Al α CTF following cleavage by γ -secretase. This observation indicates that *in vivo*, introduced Al α CTF is quickly cleaved by γ -secretase to release Al α ICD, which is free from membrane association. Indeed, *in vitro* experiments showed that Al α ICD performs a novel function in

releasing APP and Al α from X11L, different from the function of membrane-associated Al α and Al α CTF.

Strikingly, both full-length APP and Al α are released from X11L by excess expression of Al α ICD in cultured cells. These studies *in vivo* and *in vitro* strongly indicate that Al α ICD has different binding properties than full-length Al α and may be a key molecule for the regulation of APP trafficking and metabolism. As shown in Figures 2E and 4, we detected Al α ICD as a doublet. Interestingly, only the slower-migrating band interacted with X11L in co-immunoprecipitation assays (Fig. 4). Although we determined that molecular weight of the faster migrating protein band was the expected size of hAl α ICD (data not shown), we have yet to identify the modification of slower-migrating protein band and determine why it interacts differently with X11L.

Several previous reports indicated that stalling of APP transport increases the production of A β because of the increased probability of association with secretases (36-38). The source of A β is still controversial. Recent report suggested that majority of intracellular APP is transported into lysosome from Golgi to generate A β (39). In contrast, it has been thought that cell surface APP is a significant source of A β (40, 41). Our observation that the increased A β in Tg mice brain is due to the increased synaptosomal APP level may be consistent with a hypothesis that cell surface APP contributes to the increased production of A β . We revealed here that increased trafficking of APP into the late-secretory pathway facilitated APP metabolism, including A β generation, which was regulated by Al α ICD derived from Al α CTF by γ -secretase cleavage. Although the precise molecular mechanism is still under investigation, it is clear that dysfunctional APP intracellular trafficking is closely related to the aberrant production of A β . Moreover, the role of Al α ICD in the regulation of membrane protein trafficking is a novel function of regulated intramembrane proteolysis.

Acknowledgements

[¶] This work was supported in part by Grants-in-Aid for Scientific Research (26293010 to TS and 24790062 to SH) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) in Japan, and by Bilateral Joint Research Projects (SH) and Asian Core Program (TS) of Japan Society for the Promotion of Science (JSPS).

References

1. Araki, Y., Tomita, S., Yamaguchi, H., Miyagi, N., Sumioka, A., Kirino, Y., Suzuki, T. (2003) Novel cadherin-related membrane proteins, Alcadeins, enhance the X11-like protein mediated stabilization of amyloid β -protein precursor metabolism. *J. Biol. Chem.* **278**, 49448-49458.
2. Vogt, L., Schrimpf, S. P., Meskenaite, V., Frischknecht, R., Kinre, J., Leone, D. P., Ziegler, U., Sonderegger, P. (2001) Calsyntenin-1, a proteolytically processed postsynaptic membrane protein with a cytoplasmic calcium-binding domain. *Mol Cell Neurosci.* **17**, 151-166.
3. Hintsch, G., Zurlinden, A., Meskenaite, V., Steuble, M., Fink-Widmer, K., Kinter, J., Sonderegger, P. (2002) The calsyntenins -- a family of postsynaptic membrane proteins with distinct neuronal expression patterns. *Mol. Cell. Neurosci.* **21**, 393-409.
4. Araki, Y., Kawano, T., Taru, H., Saito, Y., Wada, S., Miyamoto, K., Kobayashi, H., Ishikawa, O. H., Ohsugi Y, Yamamoto, T., Matsuno, K., Kinjyo, M., Suzuki, T. (2007) The novel cargo receptor Alcadein induces vesicle association of kinesin-1 motor components and activates axonal transport. *EMBO J.* **26**, 1475-1486.
5. Araki, Y., Miyagi, N., Kato, N., Yoshida, T., Wada, S., Nishimura, M., Komano, H., Yamamoto, T., De Strooper, B., Yamamoto, K. and Suzuki, T. (2004) Coordinated metabolism of Alcadein and amyloid β -protein precursor regulates FE65-dependent gene transactivation. *J. Biol. Chem.* **279**, 24343-24354.
6. Tomita, S., Ozaki, T., Taru, H., Oguchi, S., Takeda, S., Yagi, Y., Sakiyama, S., Kirino, Y. and Suzuki, T. (1999) Interaction of a neuron-specific protein containing PDZ domains with Alzheimer's amyloid precursor protein. *J Biol. Chem.* **274**, 2243-2254.
7. Suzuki, T. and Nakaya, T. (2008) Regulation of amyloid β -protein precursor by phosphorylation and protein interactions. *J. Biol. Chem.* **283**, 29633–29637.
8. Thinakaran, G. and Koo, E. (2008) Amyloid precursor protein trafficking, processing, and function. *J. Biol. Chem.* **283**, 29615–29619.
9. Konecna, A., Frischknecht, R., Kinter, J., Ludwig, A., Steuble, M., Meskenaite, V., Indermühle, M., Engel, M., Cen, C., Mateos, J. M., Streit, P. and Sonderegger, P. (2006) Calsyntenin-1 docks vesicular cargo to kinesin-1. *Mol. Biol. Cell.* **17**, 3651-3663.
10. Hata, S., Fujishige, S., Araki, Y., Kato, N., Araseki, M., Nishimura, M., Hartmann, D., Saftig, P., Fahrenholz, F., Taniguchi, M., Urakami, K., Akatsu, H., Martins, RN., Yamamoto, K., Maeda, M., Yamamoto, T., Nakaya, T., Gandy, S. and Suzuki, T. (2009) Alcadein cleavages by APP α - and γ -secretases generate small peptides p3-Alcs indicating Alzheimer disease-related γ -secretase dysfunction. *J. Biol. Chem.* **284**, 36024-36033.
11. Hata, S., Fujishige, S., Araki, Y., Taniguchi, M., Urakami, K., Peskind E., Akatsu, H., Araseki, M., Yamamoto, K., Martins, N. R., Maeda, M., Nishimura, M., Levey, A., Chung, K. A., Montine, T., Leverenz, J., Fagan, A., Goate, A., Bateman, R., Holtzman, D. M., Yamamoto, T., Nakaya, T., Gandy, S. and Suzuki, T. (2011) Alternative γ -secretase processing of γ -secretase substrates in common forms of mild cognitive impairment and Alzheimer disease: Evidence for γ -secretase dysfunction. *Ann. Neurol.* **69**, 1026-1031.
12. Ludwig, A., Blume, J., Diep, T. M., Yuan, J., Mateos, J. M., Leuthauser, K., Steuble, M., Streit, P., Sonderegger, P. (2009) Calsyntenins mediate TGN exit of APP in a kinesin-1-dependent manner. *Traffic* **10**, 572-589.
13. Glabe, C. G. (2008) Structural classification of toxic amyloid oligomers. *J. Biol. Chem.* **283**, 29639-29643.
14. Benilova, I., Karran, E., De Strooper, B. (2012) The toxic A β oligomer and Alzheimer's disease: an emperor in need of clothes. *Nat Neurosci.* **15**, 349-357.

15. Piao, Y., Kimura, A., Urano, S., Saito, Y., Taru, H., Yamamoto, T., Hata, S. and Suzuki, T. (2013) Mechanism of intramembrane cleavage of Alcadeins by γ -secretase. *PLoS One* **8**, e62431.
16. Saito, Y., Sano, Y., Vassar, R., Gandy, S., Nakaya, T., Yamamoto, T. and Suzuki, T. (2008) X11 proteins regulate the translocation of amyloid β -protein precursor (APP) into detergent-resistant membrane and suppress the amyloidogenic cleavage of APP by β -site-cleaving enzyme in brain. *J. Biol. Chem.* **283**, 35763- 35771.
17. Saito, Y., Akiyama, M., Araki, Y., Sumioka, A., Shiono, M., Taru, H., Nakaya, Y., Yamamoto, T. and Suzuki, T. (2011) Intracellular trafficking of the amyloid β -protein precursor (APP) regulated by novel function of X11-like. *PLoS One* **6**, e22108.
18. Lau, K. F., McLoughlin, D. M., Standen, C. and Miller, C. C. (2000) X11 α and X11 β interact with presenilin-1 via their PDZ domains. *Mol. Cell. Neurosci.* **16**, 557-565.
19. Lee, J. H., Lau, K. F., Perkinson, M. S., Standen, C. L., Rogelj, B., Falinska, A., McLoughlin, D. M. and Miller, C. C. (2004) The neuronal adaptor protein X11 β reduces amyloid β -protein levels and amyloid plaque formation in the brains of transgenic mice. *J. Biol. Chem.* **279**, 49099-49104.
20. Sano, Y., Nakaya, T., Pedrini, S., Takeda, S., Iijima-Ando, K., Iijima, K., Mathews, P. M., Itohara, S., Gandy, S. and Suzuki, T. (2006) Physiological mouse brain A β levels are not related to the phosphorylation state of threonine 668 of Alzheimer APP. *PLoS ONE* **1**, e51
21. Kondo, M., Shiono, M., Itoh, G., Takei, N., Matsushima, T., Maeda, M., Taru, H., Hata, S., Yamamoto, T., Saito, Y., and Suzuki, T. (2010) Increased amyloidogenic processing of transgenic human APP in X11-like deficient mouse brain. *Mol. Neurodegener.* **5**, 35.
22. Hogan, B., Constantini, F. and Lacy E. (1986) *Manipulating the Mouse Embryo: A Laboratory Manual* (Cold Spring Harbor Laboratory Press).
23. Nakaya, T. and Suzuki, T. (2006) Role of APP phosphorylation in Fe65-dependent gene transactivation mediated by AICD. *Genes Cells* **11**, 633– 645.
24. Carlin, R. K., Grab, D. J., Cohen, R. S. and Siekevitz, P. (1980) Isolation and characterization of postsynaptic densities from various brain regions: enrichment of different types of postsynaptic densities. *J. Cell Biol.* **86**, 831-845.
25. Matsushima, T., Saito, Y., Elliott, J. I., Iijima-Ando, K., Nishimura, M., Kimura, N., Hata, S., Yamamoto, T., Nakaya, T. and Suzuki, T. (2012) Membrane-microdomain localization of amyloid β -precursor protein (APP) C-terminal fragments is regulated by phosphorylation of the cytoplasmic Thr668 residue. *J. Biol. Chem.* **287**, 19715-19724.
26. Konno, T., Hata, S., Hamada, Y., Horikoshi, Y., Nakaya, T., Saito, Y., Yamamoto, T., Yamamoto, T., Maeda, M., Gandy, S., Akatsu, H. and Suzuki, T. with Japanese Alzheimer's Disease Neuroimaging Initiative (2011) Coordinate increase of γ -secretase reaction products in the plasma of some female Japanese sporadic Alzheimer's disease patients: Quantitative analysis with a new ELISA system. *Mol. Neurodegener.* **6**, 76.
27. Nakaya, T., Kawai, T. and Suzuki, T. (2008) Regulation of FE65 nuclear translocation and function by amyloid β -protein precursor in osmotically stressed cells. *J. Biol. Chem.* **283**, 19119-19131.
28. Brown, M. S., Ye, J., Rawson, R. B. and Goldstein, J. L. (2000) Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. *Cell.* **100**, 391-398.
29. Morohashi, Y. and Tomita, T. (2013) Protein trafficking and maturation regulate intramembrane proteolysis. *Biochem. Biophys. Acta.* **1828**, 2855-2861.
30. McLoughlin, D. M., Irving, N. G., Brownlee, J., Brion, J. P., Leroy, K. and Miller, C. C. (1999) Mint2/X11-like colocalizes with the Alzheimer's disease amyloid precursor protein and is associated with neuritic plaques in Alzheimer's disease. *Eur. J. Neurosci.* **11**, 1988-1994.
31. Xie, Z., Romano, D. M. and Tanzi, R. E. (2005) RNA interference-mediated silencing of X11 α and X11 β attenuates amyloid β -protein levels via differential effects on β -amyloid precursor protein processing. *J. Biol. Chem.* **280**, 15413-15421.
32. Ho, A., Liu, X. and Südhof, T. C. (2008) Deletion of Mint proteins decreases amyloid production in transgenic mouse models of Alzheimer's disease. *J. Neurosci.* **28**, 14392-14400.
33. Chauftly, J., Sullivan, S. E. and Ho, A. (2012) Intracellular amyloid precursor protein sorting and amyloid- β secretion are regulated by Src-mediated phosphorylation of Mint2. *J. Neurosci.* **32**, 9613-9625.

34. Saluja, I., Paulson, H., Gupta, A. and Turner, R. S. (2009) X11 α haploinsufficiency enhances A β amyloid deposition in Alzheimer's disease transgenic mice. *Neurobiol. Dis.* **36**, 162-168.
35. Mitchell, J. C., Ariff, B. B., Yates, D. M., Lau, K. F., Perkinton, M. S., Rogelj, B., Stephenson, J. D., Miller, C. C. and McLoughlin, D. M. (2009) X11 β rescues memory and long-term potentiation deficits in Alzheimer's disease APPswe Tg2576 mice. *Hum. Mol. Genet.* **18**, 4492-4500.
36. Kamal, A., Stokin, G. B., Yang, Z., Xia, C. H. and Goldstein, L. S. (2000) Axonal transport of amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-I. *Neuron* **28**, 449-459.
37. Stokin, G. B., Lillo, C., Falzone, T. L., Brusch, R. G., Rockenstein, E., Mount, S. L., Raman, R., Davies, P., Masliah, E., Williams, D. S. and Goldstein, L. S. (2005) Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. *Science* **307**, 1282-1288.
38. Almenar-Queralt, A., Falzone, T. L., Shen, Z., Lillo, C., Killian, R. L., Arreola, A. S., Niederst, E. D., Ng, K. S., Kim, S. N., Briggs, S. P., Williams, D. S. and Goldstein, L. S. (2014) UV irradiation accelerates amyloid precursor protein (APP) processing and disrupts APP axonal transport. *J. Neurosci.* **34**, 3320-3339.
39. Tam, J. H. K., Seah, C. and Pasternak, S. H. (2014) The amyloid precursor protein is rapidly transported from the Golgi apparatus to the lysosome and where it is processed into beta-amyloid. *Mol. Brain* **7**:54.
40. Koo, E. H. and Squazzo, S. L. (1994) Evidence that production and release of amyloid beta-protein involves the endocytic pathway. *J. Biol. Chem.* **269**, 17386-17389.
41. Grbovic, O. M., Matthews, P. M., Jiang, Y., Schmidt, S.D., Dinakar, R., Summers-Terio, N. B., Ceresa, B. P., Nixon, R. A. and Cataldo, A. M. (2003) Rab5-stimulated up-regulation of the endocytic pathway increases intracellular beta-cleaved amyloid precursor protein carboxyl-terminal fragment levels and Abeta production. *J. Biol. Chem.* **178**, 31261-31268.

Foots Notes

Abbreviations: AD, Alzheimer disease; A β , amyloid β -protein; APP, amyloid β -protein precursor; Alc, Alcadein; X11L, X11-like; CTF, carboxyl-terminal fragment; ICD, intra cellular domain fragment; Tg, transgenic; RIP, regulated intramembrane proteolysis; DAPT, (3,5-Difluorophenylacetyl)-Ala-Phg-OBu^t.

Figure legends

Figure 1. Generation and characterization of hAlc α CTF transgenic mouse lines.

A. Construct for generation of hAlc α CTF transgenic mouse lines. The cDNA sequence encoding amino acids 817-971 of human Alc α 1 (971 amino acids) was ligated with cDNA encoding the signal sequence (amino acids 1 to 28) and cloned into a vector with the 5' PDGF- β promoter sequence and 3' SV40 poly A sequence. DNA fragments prepared by digestion with *SalI* and *NotI* were used for injection into fertilized eggs.

B. Identification of human p3-Alc α secreted from HEK293 cells expressing hAlc α CTF. Amino acid sequence of human p3-Alc α 35 and a representative MS spectrum of immunoprecipitate recovered from medium of HEK293 cells expressing human Alc α CTF with anti-p3-Alc α antibody UT135 are shown. Parenthesized numbers indicate p3-Alc α species ("35" indicates p3-Alc α 35, a major p3-Alc α specie).

C. Establishment of hAlc α CTF Tg mouse founders. Summary of the individual numbers at the respective experimental stages.

D. Genomic Southern blot analysis of six transgenic lines. Genomic DNA of six founders was analyzed by Southern blotting with DNA fragments prepared by *SalI/NotI* digestion (panel A) as a probe. The transgenic lines used are numbered, along with non-transgenic mouse (Non-Tg) DNA and ten copies of injected DNA.

E. Expression levels of hAlc α CTF in three Tg mice lines. Protein expression of hAlc α CTF, a transgenic product, was quantified by immunoblotting. A brain region including the cerebral cortex and hippocampus of Tg18, Tg47 and Tg54 mice along with their non-Tg littermates (N) was lysed and analyzed by immunoblotting with anti-Alc α #958 (upper) and anti-flotillin-1 (lower) antibodies. Band densities of Alc α CTF were quantified and standardized with respect to the band density of flotillin-1. Expression levels in Tg mice (closed column) are shown as a ratio relative to the endogenous Alc α CTF level of non-Tg littermates (open column), which was set at 1.0. Data represent mean $\pm$ S.E. (n = 3). Specificity of the anti-Alc α #958 antibody is shown in Figure 2A.

Figure 2. Expression of hAlc α CTF in the brains of Tg54 mice

A. Specificity of anti-Alc α carboxyl-terminal domain antibody #958. Lysates of HEK293 cells expressing human FLAG-Alc α (lane 2), human FLAG-Alc β (lane 3) and human FLAG-Alc γ (lane 4) along with plasmid alone (lane 1) were analyzed by immunoblotting with anti-FLAG M2 (left) and anti-Alc α #958 (right) antibodies. The arrow indicates FLAG-tagged Alc α , Alc β and Alc γ , and the arrowhead indicates Alc α CTF. Numbers indicate protein standards (kDa). The asterisk indicates a non-specific product.

B. Expression of hAlc α CTF in the brain regions of Tg54 mice. Expression of hAlc α CTF in brain regions of Tg54 mice was examined by immunoblotting with #958 antibody.

Brain tissue from 3-month-old Tg54 (Tg) and non-Tg (N) littermates were dissected into the indicated brain regions and lysates obtained from these sections were analyzed by immunoblotting with #958 (upper) and anti- β -actin (lower) antibodies. OB, olfactory bulb; CC, cerebral cortex; Hipp, hippocampus; Th/Hy, thalamus/hypothalamus; St, striatum; Mid, midbrain; Me, medulla; Ce, cerebellum; Sc, spinal cord.

C. Localization of hAlc α CTF in the brains of Tg54 mice. Localization of hAlc α CTF in brain regions was examined by immunostaining with #958 antibody. Sections of the cerebral cortex (a, d), hippocampus (b, e) and olfactory bulb (c, f) were prepared from 3-month-old Tg54 (d-f) and non-Tg (a-c) littermates and immunostained. Py, pyramidal cells; Gr, granule cells; DG, dentate gyrus; MCL, mitral cell layer; GL, granule cell layer.

D. Quantification of p3-Alc α in the brains of Tg54 mice. The total amount of p3-Alc α in the brains of 6-month-old Tg54 (Tg, closed column) and non-Tg (N, open column) littermates were quantified by sELISA. Quantified values are given as the mean $\pm$ S.E. (n = 4). ***, p < 0.005, Student's t-test. #, below detectable levels.

E. Detection of hAlc α ICD in the cytosolic fraction of mice brains. Brain lysates prepared from 2-month-old Tg54 (Tg) and non-Tg (N) mice brains were subject to immunoprecipitation with #958 antibody and the precipitates were detected by immunoblotting with the same antibody. Arrows indicate hAlc α ICD fragments. Number on the left side of the panel indicates the molecular weight (kDa). Asterisks indicate IgG heavy and light chains.

F. Schematic structure of p3-Alc α and hAlc α ICD. Alc α CTF is first cleaved at the ϵ -site by γ -secretase to release Alc α ICD into the cytoplasm. Next, γ -secretase cleavages reach to the γ -site to secrete p3-Alc α into the extracellular milieu (15).

Figure 3. Changes in APP metabolism in the brains of Tg54 mice.

A. Quantification of A β ¹⁻⁴⁰ and A β ¹⁻⁴² in brain tissue of Tg54 and non-Tg mice. Brain regions including the cerebral cortex and hippocampus of 12- to 15-month-old Tg54 (closed column) and non-Tg (open column) mice were dissected, and endogenous A β ¹⁻⁴⁰ (left) and A β ¹⁻⁴² (right) in the TBS-soluble and -insoluble fractions were quantified by sELISA. Results are given as the means $\pm$ S.E. Asterisks indicate statistical significance as determined by Student's *t*-test ($n = 12$, ** $p < 0.01$).

B. Subcellular localization of APP and APP CTFs in Tg54 and non-Tg brains. Brain regions including the cerebral cortex and hippocampus of 12-month-old Tg54 (Tg) and non-Tg (N) littermates were fractionated and analyzed by immunoblotting with antibodies against the indicated proteins: anti-APP (#8717, Sigma) for APP CTFs and APP FL, anti-Alc α (#958) for Alc α CTF, anti-flotillin-1 (BD Bioscience), anti-synaptophysin (SY38, DAKO), anti-GM130 (BD Bioscience) and anti- α -tubulin (sc-32293, Santa Cruz). Full-length APP (APP FL), mature (mAPP with *N*- and *O*-glycosylation) and immature (imAPP with *N*-glycosylation) APP695 are indicated. C99 and C89 indicate CTF β , and C83 indicates CTF α . The pC99, pC89 and pC83 are CTFs phosphorylated at Thr668 (A schematic blot of detected CTFs is indicated in lower right). Lys, total lysate; S1, post-nuclear supernatant; S2 and P2, supernatant and pellet of S1 fraction which was subjected to further centrifugation; Syn, synaptosome fraction. Numbers at left side represent protein molecular weight standards. Arrows at right side indicate the protein detected with antibodies. The bar graphs show the results of quantification of protein bands in the total lysate (Lys) and synaptosome fractions (Syn). Quantified values of APP FL (far left graph) and APP CTFs (middle graph) in the lysate and synaptosome fractions are indicated. The pC99 was also quantified, and the ratio of pC99/total CTFs (right graph) is shown. Values were normalized to the values of flotillin-1. Values obtained from non-Tg mice were set to 1.0 and are given as the mean $\pm$ S.E. Asterisks indicate statistical significance as determined by Student's *t*-test ($n = 5$, * $p < 0.05$).

Figure 4. Facilitation of APP and Alc α release from the APP/X11L/Alc α ternary complex by Alc α ICD.

A. Co-immunoprecipitation of ternary complex components in the presence of hAlc α ICD. Neuro2a cells expressing human APP-GFP (hAPP-GFP), full-length Alc α (Alc α FL) and FLAG-X11L with or without hAlc α ICD were analyzed for formation of a ternary complex composed of APP, X11L and Alc α . Proteins in cell lysates (lanes 1–4) were subjected to immunoprecipitation with anti-FLAG antibody and co-immunoprecipitated proteins (IP) were analyzed by immunoblotting with antibodies (lanes 5–8); anti-GFP (#598, MBL), anti-Alc α (UT83) (1) and anti-FLAG (M2, Sigma).

B. Quantification of APP and Alc α recovered by co-immunoprecipitation assay. Protein band densities of hAPP-GFP (open circle) and hAlc α FL (closed circle) co-immunoprecipitated with FLAG-X11L were quantified and are shown relative to the value obtained in the absence of hAlc α ICD expression (0, set to 1.0). The horizontal axis represents the amount of pcDNA3-hAlc α ICD (μ g) co-transfected with pcDNA3-hAPP-GFP (1 μ g), pcDNA3-hAlc α (1 μ g) and pcDNA3-FLAG-X11L (0.5 μ g). Results are given as the means $\pm$ S.E. Asterisks indicate statistical significance as determined by Student's *t*-test ($n = 3$, * $p < 0.05$).

Figure 5. Alc α ICD facilitates the trafficking of APP into neurites.

A. The proximal region of neurites for analysis of APP trafficking. Neuro2a cells were observed under a transmission light and the hillock of cell body (asterisk, “cell body”) and the proximal region

of neurite (triangle, “neurite”) were analyzed for EGFP-APP fluorescence as described in Experimental Procedures.

B. Representative images of the fluorescence of EGFP-APP. The fluorescence of EGFP-APP was observed in living cells expressing HA-X11L and Alca CTF in the presence (lower) or absence (upper) of Alca ICD expression. Analyses were performed in the presence or absence of DAPT treatment (10 μ M for 4h).

C. Quantifications of fluorescence intensities of EGFP-APP at the proximal region of neurites. The intensities of EGFP-APP in panel B were quantified. Left half indicates the intensity of “cell body” and right half indicates the intensity of “neurite”. The fluorescence intensity of “cell body” or “neurite” is shown as a ratio to average intensity of “cell body” plus “neurite”. Black (control) and gray (DAPT treated) lines are shown. The values are indicated with mean $\pm$ SEM. $n = 9 - 14$. * $< p = 0.05$, Student's t -test.

D. Levels of protein expression in cells. Lysates of Neuro2a cells with or without DAPT treatment were analyzed by immunoblotting with anti-GFP #598 (MBL), anti-HA 12CA5 (Roche), and anti-Alca 958 (for Alca CTF and Alca ICD) antibodies. Detected proteins are indicated with arrowheads. Transfection of plasmids is indicated with “+”, while “-” indicates the use of empty plasmid alone. Numbers indicate the protein molecular weight standards.

Fig. 1




Fig. 2




Fig. 3




Fig. 4





Fig. 5

